Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 9Neuroendocrine Tumors 8Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 5Stomach Neoplasms 4Sarcoma 4Cholangiocarcinoma 4Ovarian Neoplasms 3Osteosarcoma 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Neuroectodermal Tumors, Primitive 1NSCLC 1Lymphoma 1Locally Advanced Pancreatic Cancer 1

Interventions

Everolimus 8Temozolomide 7Sunitinib 6Specimen Handling 4Octreotide 4Magnetic Resonance Spectroscopy 4Fluorouracil 4Capecitabine 4lutetium Lu 177 dotatate 3Leucovorin 3sargramostim 2montanide ISA 51 2incomplete Freund's adjuvant 2cabozantinib 2Thalidomide 2Streptozocin 2Oxaliplatin 2Irinotecan 2Injections 2Doxorubicin 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1sapanisertib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1nimotuzumab 1napabucasin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenoma, Islet Cell × surufatinib × Clear all
NCT06158516 2023-12-06

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Changhai Hospital

Phase 2 Not yet recruiting
100 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡